Wells Fargo initiated coverage on BridgeBio Pharma with a new price target

12/8/23 7:24:30 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Wells Fargo initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $58.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BBIO

Date	Price Target	Rating	Analyst
6/17/2025	$49.00	Outperform	Wolfe Research
3/31/2025	$50.00	Buy	Redburn Atlantic
10/16/2024		Sector Outperform	Scotiabank
10/3/2024		Perform	Oppenheimer
9/4/2024	$46.00	Overweight	Piper Sandler
3/21/2024	$45.00	Outperform	Raymond James
1/31/2024	$37.00	Market Perform	BMO Capital Markets
12/8/2023	$58.00	Overweight	Wells Fargo